Back to Markets
ACAC Immune SA

AC Immune SA

ACIUNASDAQ NMS - GLOBAL MARKET
Health CareBiotechnology

$2.66

-0.090000 (-3.27%)

As of 05/29/26 EDT · USD

Compare
Low: $1.60Current: $2.66High: $4.00

Key Statistics

Open

$2.73

Day High

$2.78

Day Low

$2.65

Prev. Close

$2.75

VolumeShares traded today.

291.70K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$270.72M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-3.22

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$4.00

52W LowLowest price over the past 52 weeks.

$1.60

50D MAAverage closing price over the last 50 trading days.

$2.92

200D MAAverage closing price over the last 200 trading days.

$2.96

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

-6.7%

1M

-9.2%

6M

-8.3%

YTD

-20.8%

1Y

+55.6%

About

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

www.acimmune.com/

Company Facts

SectorHealth Care
IndustryBiotechnology
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade ACIU

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.